<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        80-249-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ESURAL 20 mg Delayed Release Tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ESOMEPRAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Delayed-release tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        47.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="APOTEX INC. (SIGNET SITE)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            APOTEX INC. (SIGNET SITE)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            APOTEX INC. (SIGNET SITE)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A02BC05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Esural contains a medicine called esomeprazole. This belongs to a group of medicines called &rsquo;proton pump inhibitors&rsquo;. They work by reducing the amount of acid that your stomach produces.<br />&nbsp;<br />Esural is used to treat the following conditions:&nbsp;</p><p><strong>Adults and adolescents aged 12 years and above:</strong></p><ul><li>&lsquo;Gastroesophageal reflux disease&rsquo; (GERD). This is where acid from the stomach escapes into the gullet (the tube which connects your throat to your stomach) causing pain, inflammation and heartburn.&nbsp;</li><li>Ulcers in the stomach or upper part of the gut (intestine) that are infected with bacteria called &lsquo;Helicobacter pylori&rsquo;. If you have this condition, your doctor may also prescribe antibiotics to treat the infection and allow the ulcer to heal.&nbsp;</li></ul><p>&nbsp;</p><p><strong>Adults:</strong></p><ul><li>Stomach ulcers caused by medicines called NSAIDs (NonSteroidal Anti-Inflammatory Drugs). Esural can also be used to stop stomach ulcers from forming if you are taking NSAIDs.&nbsp;</li><li>Too much acid in the stomach caused by a growth in the pancreas (Zollinger-Ellison syndrome).&nbsp;</li><li>Prolonged treatment after prevention of rebleeding of ulcers with intravenous esomeprazole.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Esural</strong></p><ul><li>if you are allergic to esomeprazole or any of the other ingredients of this medicine (listed in Section 6).&nbsp;</li><li>if you are allergic to other proton pump inhibitor medicines (e.g. pantoprazole, lanzoprazole, rabeprazole, omeprazole).&nbsp;</li><li>if you are taking a medicine containing nelfinavir (used to treat HIV infection).&nbsp;</li></ul><p>Do not take Esural if any of the above applies to you. If you are not sure, talk to your doctor or pharmacist before taking Esural.&nbsp;</p><p>&nbsp;</p><p><strong>Warnings and precautions&nbsp;</strong><br />Talk to your doctor or pharmacist before taking Esural:&nbsp;</p><ul><li>if you have severe liver problems.&nbsp;</li><li>if you have severe kidney problems.&nbsp;</li></ul><p>&nbsp;</p><p>Esural may hide the symptoms of other diseases. <strong>Therefore, if any of the following happen to you before you start taking Esural or while you are taking it, talk to your doctor straight away:&nbsp;</strong></p><ul><li>you lose a lot of weight for no reason and have problems swallowing.&nbsp;</li><li>you get stomach pain or indigestion.&nbsp;</li><li>you begin to vomit food or blood.&nbsp;</li><li>you pass black stools (blood-stained faeces).&nbsp;</li></ul><p>If you have been prescribed Esural &ldquo;on demand&rdquo; you should contact your doctor if your symptoms continue or change in character.&nbsp;</p><p>Taking a proton pump inhibitor like Esural, especially over a period of more than one year, may slightly increase your risk of fracture in the hip, wrist or spine. Tell your doctor if you have osteoporosis or if you are taking corticosteroids (which can increase the risk of osteoporosis).</p><p>&nbsp;</p><p><strong>Children under the age of 12 years&nbsp;</strong><br />Esural should not be used in children younger than 12 years. More appropriate pharmaceutical forms of this medicine may be available.&nbsp;</p><p>&nbsp;</p><p><strong>Other medicines and Esural</strong><br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines that you buy without a prescription. This is because Esural can affect the way some medicines work and some medicines can have an effect on Esural.&nbsp;<br />Do not take Esural if you are taking a medicine containing nelfinavir (used to treat HIV infection).&nbsp;</p><p>&nbsp;</p><p><strong>Tell your doctor or pharmacist if you are taking any of the following medicines:&nbsp;</strong></p><ul><li>Atazanavir (used to treat HIV infection).&nbsp;</li><li>Clopidogrel (used to prevent blood clots).&nbsp;</li><li>Ketoconazole, itraconazole or voriconazole (used to treat infections caused by a fungus).&nbsp;</li><li>Erlotinib (used to treat cancer).&nbsp;</li><li>Citalopram, imipramine or clomipramine (used to treat depression).&nbsp;</li><li>Diazepam (used to treat anxiety, relax muscles or in epilepsy).&nbsp;</li><li>Phenytoin (used in epilepsy). If you are taking phenytoin, your doctor will need to monitor you when you start or stop taking Esural.&nbsp;</li><li>Medicines that are used to thin your blood, such as warfarin. Your doctor may need to monitor you when you start or stop taking Esural.&nbsp;</li><li>Cilostazol (used to treat intermittent claudication &ndash; a pain in your legs when you walk which is caused by an insufficient blood supply).&nbsp;</li><li>Cisapride (used for indigestion and heartburn).&nbsp;</li><li>Digoxin (used for heart problems).&nbsp;</li><li>Methotrexate (a chemotherapy medicine used in high doses to treat cancer) &ndash; if you are taking a high dose of methotrexate, your doctor may temporarily stop your Esural treatment.&nbsp;</li><li>Tacrolimus (organ transplantation).&nbsp;</li><li>Rifampicin (used for treatment of tuberculosis).&nbsp;</li><li>St John&rsquo;s wort (Hypericum perforatum) (used to treat depression).&nbsp;</li></ul><p>If your doctor has prescribed the antibiotics amoxicillin and clarithromycin as well as Esural to treat ulcers caused by Helicobacter pylori infection, it is very important that you tell your doctor about any other medicines you are taking.&nbsp;</p><p>&nbsp;</p><p><strong>Esural with food and drink&nbsp;</strong><br />You can take your tablets with food or on an empty stomach.&nbsp;</p><p>&nbsp;</p><p><strong>Pregnancy, breastfeeding and fertility&nbsp;</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.&nbsp;<br />Your doctor will decide whether you can take Esural during this time.&nbsp;<br />It is not known if esomeprazole passes into breast milk. Therefore, you should not take Esural if you are breastfeeding.&nbsp;</p><p>&nbsp;</p><p><strong>Driving and using machines&nbsp;</strong><br />Esural is not likely to affect your ability to drive or use any tools or machines. However, side effects such as dizziness and blurred vision may uncommonly or rarely occur (see section 4). If affected, you should not drive or use machines.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.&nbsp;</p><ul><li>If you are taking this medicine for a long time, your doctor will want to monitor you (particularly if you are taking it for more than a year).&nbsp;</li><li>If your doctor has told you to take this medicine as and when you need it, tell your doctor if your symptoms change.&nbsp;</li></ul><p>&nbsp;</p><p><strong>How much to take</strong></p><ul><li>Your doctor will tell you how many tablets to take and how long to take them for. This will depend on your condition, how old you are and how well your liver works.&nbsp;</li><li>The recommended doses are given below.&nbsp;</li></ul><p>&nbsp;</p><p><u>To treat heartburn caused by gastroesophageal reflux disease (GERD):&nbsp;</u><br />&nbsp;</p><p>Adults and adolescents aged 12 years or above:</p><ul><li>If your doctor has found that your food pipe (gullet) has been slightly damaged, the recommended dose is one tablet of Esural 40mg once a day for 4 weeks. Your doctor may tell you to take the same dose for a further 4 weeks if your gullet has not yet healed.&nbsp;</li><li>The recommended dose once the gullet has healed is one tablet of Esural 20mg once a day.&nbsp;</li><li>If your gullet has not been damaged, the recommended dose is one tablet of Esural 20mg each day. Once the condition has been controlled, your doctor may tell you to take your medicine as and when you need it, up to a maximum of one tablet of Esural 20mg each day.&nbsp;</li><li>If you have severe liver problems, your doctor may give you a lower dose.&nbsp;</li></ul><p>&nbsp;</p><p><u>To treat ulcers caused by Helicobacter pylori infection and to stop them coming back:&nbsp;</u></p><ul><li>Adults and adolescents aged 12 or above: the recommended dose is one tablet of Esural 20mg twice a day for one week.&nbsp;</li><li>Your doctor will also tell you to take antibiotics, for example amoxicillin and clarithromycin.</li></ul><p>&nbsp;</p><p><u>To treat stomach ulcers caused by NSAIDs (Non-Steroidal Anti-Inflammatory Drugs):&nbsp;</u><br />Adults aged 18 and above: the recommended dose is one tablet of Esural 20mg once a day for 4 to 8 weeks.&nbsp;</p><p>&nbsp;</p><p><u>To prevent stomach ulcers if you are taking NSAIDs (Non-Steroidal Anti-Inflammatory Drugs):&nbsp;</u></p><ul><li>Adults aged 18 and above: the recommended dose is one tablet of Esural 20mg once a day.&nbsp;</li></ul><p>&nbsp;</p><p><u>To treat too much acid in the stomach caused by a growth in the pancreas (Zollinger-Ellison syndrome):&nbsp;</u></p><ul><li>Adults aged 18 and above: the recommended dose is one tablet of Esural 40mg twice a day.&nbsp;</li><li>Your doctor will adjust the dose depending on your needs and will also decide how long you need to take the medicine for. The maximum dose is 80 mg twice a day.&nbsp;</li></ul><p>&nbsp;</p><p><u>To be used as prolonged treatment after prevention of rebleeding of ulcers with intravenous esomeprazole:&nbsp;</u></p><ul><li>Adults aged 18 years and above: the recommended dose is one tablet of Esural 40mg once a day for 4 weeks.</li></ul><p>&nbsp;</p><p><strong>Taking this medicine&nbsp;</strong></p><ul><li>You can take your tablets at any time of the day.&nbsp;</li><li>You can take your tablets with food or on an empty stomach.&nbsp;</li><li>Swallow your tablets whole with a drink of water. Do not chew or crush the tablets. This is because the tablets contain coated pellets which stop the medicine from being broken down by the acid in your stomach. It is important not to damage the pellets.</li></ul><p>&nbsp;</p><p><strong>What to do if you have trouble swallowing the tablets&nbsp;</strong></p><ul><li>If you have trouble swallowing the tablets:&nbsp;<ul><li>Put them into half a glass of still (nonfizzy) water. Do not use any other liquids.&nbsp;</li><li>Stir until the tablets break up (the mixture will not be clear). Then drink the mixture straight away or within 30 minutes. Always stir the mixture just before drinking it.&nbsp;</li><li>To make sure that you have drunk all of the medicine, rinse the glass very well with half a glass of water and drink it. The solid pieces contain the medicine - do not chew or crush them.&nbsp;</li><li>If you cannot swallow at all, the tablet can be mixed with some water and put into a syringe. It can then be given to you through a tube directly into your stomach (&lsquo;gastric tube&rsquo;).&nbsp;</li></ul></li></ul><p>&nbsp;</p><p><strong>Children under the age of 12 years&nbsp;</strong><br />Esural should not be used in children younger than 12 years. More appropriate pharmaceutical forms of this medicine may be available.&nbsp;</p><p>&nbsp;</p><p><strong>Older people&nbsp;</strong><br />Dose adjustment is not required in the elderly.&nbsp;</p><p>&nbsp;</p><p><strong>If you take more Esural than you should&nbsp;</strong><br />If you take more Esural than prescribed by your doctor, talk to your doctor or pharmacist straight away.&nbsp;</p><p>&nbsp;</p><p><strong>If you forget to take Esural</strong></p><ul><li>If you forget to take a dose, take it as soon as you remember it. However, if it is almost time for your next dose, skip the missed dose.&nbsp;</li><li>Do not take a double dose (two doses at the same time) to make up for a forgotten dose.&nbsp;</li></ul><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like any drug, Esural may cause side effects in some people. Side effects that do occur are usually mild. They usually go away a short time after starting Esural. These side effects may not be caused by Esural in your case, but only a doctor can assess this. If these become bothersome (or exceed 1-2 days), discuss with your doctor.</p><p>&nbsp;</p><p><strong>If you notice any of the following serious side effects, stop taking Esural and contact a doctor immediately:&nbsp;</strong></p><ul><li>Sudden wheezing, swelling of your lips, tongue and throat or body, rash, fainting or difficulties in swallowing (severe allergic reaction).&nbsp;</li><li>Reddening of the skin with blisters or peeling. There may also be severe blisters and bleeding in the lips, eyes, mouth, nose and genitals. This could be &lsquo;Stevens-Johnson syndrome&rsquo; or &lsquo;toxic epidermal necrolysis&rsquo;.&nbsp;</li><li>Yellow skin, dark urine and tiredness which can be symptoms of liver problems.&nbsp;</li></ul><p>These effects are rare (may affect up to 1 in 1,000 people).&nbsp;</p><p>&nbsp;</p><p><strong>Other side effects include:&nbsp;</strong></p><p>&nbsp;</p><p><u>Common (may affect up to 1 in 10 people)&nbsp;</u></p><ul><li>Headache.&nbsp;</li><li>Effects on your stomach or gut: diarrhoea, stomach pain, constipation, wind (flatulence).&nbsp;</li><li>Feeling sick (nausea) or being sick (vomiting).&nbsp;</li></ul><p>&nbsp;</p><p><u>Uncommon (may affect up to 1 in 100 people)&nbsp;</u></p><ul><li>Swelling of the feet and ankles.&nbsp;</li><li>Disturbed sleep (insomnia).&nbsp;</li><li>Dizziness, tingling feelings such as &ldquo;pins and needles&rdquo;, feeling sleepy.&nbsp;</li><li>Spinning feeling (vertigo).&nbsp;</li><li>Dry mouth.&nbsp;</li><li>Changes in blood tests that check how the liver is working.&nbsp;</li><li>Skin rash, lumpy rash (hives) and itchy skin.&nbsp;</li><li>Fracture of the hip, wrist or spine (if Esural is used in high doses and over long duration).&nbsp;</li></ul><p>&nbsp;</p><p><u>Rare (may affect up to 1 in 1,000 people)&nbsp;</u></p><ul><li>Blood problems such as a reduced number of white cells or platelets. This can cause weakness, bruising or make infections more likely.&nbsp;</li><li>Low levels of sodium in the blood. This may cause weakness, being sick (vomiting) and cramps.&nbsp;</li><li>Feeling agitated, confused or depressed.&nbsp;</li><li>Taste changes.&nbsp;</li><li>Eyesight problems such as blurred vision.&nbsp;</li><li>Suddenly feeling wheezy or short of breath (bronchospasm).&nbsp;</li><li>An inflammation of the inside of the mouth.</li><li>An infection called &ldquo;thrush&rdquo; which can affect the gut and is caused by a fungus.&nbsp;</li><li>Liver problems, including jaundice which can cause yellow skin, dark urine, and tiredness.&nbsp;</li><li>Hair loss (alopecia).&nbsp;</li><li>Skin rash on exposure to sunshine.&nbsp;</li><li>Joint pains (arthralgia) or muscle pains (myalgia).&nbsp;</li><li>Generally feeling unwell and lacking energy.&nbsp;</li><li>Increased sweating.&nbsp;</li></ul><p>&nbsp;</p><p><u>Very rare (may affect up to 1 in 10,000 people)&nbsp;</u></p><ul><li>Changes in blood count including agranulocytosis (lack of white blood cells).&nbsp;</li><li>Aggression.&nbsp;</li><li>Seeing, feeling or hearing things that are not there (hallucinations).&nbsp;</li><li>Severe liver problems leading to liver failure and inflammation of the brain.&nbsp;</li><li>Sudden onset of a severe rash or blistering or peeling skin. This may be associated with a high fever and joint pains (Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis).&nbsp;</li><li>Muscle weakness.&nbsp;</li><li>Severe kidney problems.&nbsp;</li><li>Enlarged breasts in men.&nbsp;</li></ul><p>&nbsp;</p><p><u>Not known (frequency cannot be estimated from the available data)&nbsp;</u></p><ul><li>If you are on Esural for more than three months it is possible that the levels of magnesium in your blood may fall. Low levels of magnesium can be seen as fatigue, involuntary muscle contractions, disorientation, convulsions, dizziness or increased heart rate. If you get any of these symptoms, please tell your doctor promptly. Low levels of magnesium can also lead to a reduction in potassium or calcium levels in the blood. Your doctor may decide to perform regular blood tests to monitor your levels of magnesium.&nbsp;</li><li>Inflammation in the gut (leading to diarrhoea).&nbsp;</li></ul><p>&nbsp;</p><p>Esural may in very rare cases affect the white blood cells leading to immune deficiency. If you have an infection with symptoms such as fever with a severely reduced general condition or fever with symptoms of a local infection such as pain in the neck, throat or mouth or difficulties in urinating, you must consult your doctor as soon as possible so that a lack of white blood cells (agranulocytosis) can be ruled out by a blood test. It is important for you to give information about your medication at this time.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Store below 30&deg;C. Protect from moisture.</li><li>Do not keep Esural in the bathroom medicine cabinet or other warm moist places.</li><li>Keep Esural well out of the reach and sight of children.</li><li>Do not used Esural after the expiry date marked on the pack.</li><li>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>The active substance is Esomeprazole Magnesium.&nbsp;</li><li>Each Esural 20 mg tablet contains 20 mg esomeprazole (as esomeprazole magnesium).&nbsp;</li><li>Each Esural 40 mg tablet contains 40 mg esomeprazole (as esomeprazole magnesium).&nbsp;<br />&nbsp;</li></ul><p>Esural contains the following nonmedicinal ingredients (listed in alphabetical order): colloidal silicon dioxide, copovidone, magnesium stearate, methacrylic acid copolymer type C, red ferric oxide, TALC, titanium dioxide, triethyl citrate and yellow ferric oxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Pharmaceutical form
Tablets – 20 & 40 mg

Physical description
Esural 20 mg tablet is light pink, oval, biconvex, enteric-coated tablet. Engraved “ES20” on one side, other side plain.
Esural 40 mg tablet is dusty rose, oval, biconvex, enteric-coated tablet. Engraved “ES40” on one side, other side plain.

Contents of the pack
The tablets are available in blister packs of 20 tablets or 30 tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Apotex Incorporated</p><p>150 Signet Drive</p><p>Toronto, Ontario</p><p>Canada, M9L 1T9</p><p>Tel:1-800-268-4623</p><p>Fax:1-800-609-9444</p><p>www.apotex.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised on 06/2017
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>تحتوي أقراص إزيورال على دواء يُسمى إيزومبيرازول، ينتمي هذا الدواء لمجموعة من الأدوية تُسمى &laquo;مُثبطات ضخ البروتون&raquo;. تعمل هذه المثبطات على خفض كمية الحمض التي تقوم المعدة بإفرازها.<br />&nbsp;<br />يُستخدم إزيورال في علاج الحالات التالية:&nbsp;</p><p><strong>البالغين واليافعين من عمر 12 عام فما فوق:</strong></p><ul><li>&laquo;داء ارتجاع حمض المعدة&raquo; (GERD). وهي الحالة التي ينتقل فيها الحمض من المعدة إلى المريء (الأنبوب الذي يصل بين الحلق والمعدة) ويُسبب الألم والالتهاب وحرقة المعدة.&nbsp;</li><li>قُرح المعدة أو القرح في الجزء الأعلى من الأحشاء (الأمعاء) التي تُسببها البكتيريا الملوية البوابية. إذا كانت هذه هي حالتك، قد يصف لك الطبيب أيضًا مضادات حيوية لعلاج العدوى والمساعدة على شفاء القرحة.&nbsp;</li></ul><p>&nbsp;</p><p><strong>البالغين:</strong></p><ul><li>قرح المعدة التي تتسبب بها الأدوية غير الستيرويدية المضادة للالتهاب (NSAIDs). يمكن استخدام إزيورال أيضًا في إيقاف تكون قرح المعدة إذا كنت ممن يتناولون الأدوية غير الستيرويدية المضادة للالتهاب.&nbsp;</li><li>زيادة الحمض في المعدة والتي يتسبب بها نمو في البنكرياس (متلازمة زولينجر-إليسون [فرط إفراز حمض المعدة بسبب ورم الغاسترين]).&nbsp;</li><li>العلاج المطول بعد منع القرح من النزف مرة أخرى عن طريق الحقن الوريدي لدواء الإيزومبيرازول.<br />&nbsp;</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تتناول عقار إزيورال</strong></p><ul><li dir="rtl">إذا كنت مُصابًا بالحساسية تجاه دواء إيزومبيرازول أو أي مكون من المكونات الأخرى في هذا العقار (المُدرجة في القسم 6).&nbsp;</li><li dir="rtl">إذا كنت مُصابًا بحساسية تجاه الأدوية الأخرى المثبطة لضخ البروتون (مثل بانتوبرازول، لانزوبرازول، رابيبرازول، أوميبرازول).&nbsp;</li><li dir="rtl">إذا كنت تتناول دواء يحتوي على النيلفينافير (يُستخدم في علاج مرض الإيدز).&nbsp;</li></ul><p>لا تتناول عقار إزيورال إذا كان أي مما سبق ينطبق عليك. في حال عدم التأكد، تحدث مع طبيبك أو الصيدلي قبل تناول عقار إزيورال.&nbsp;</p><p>&nbsp;</p><p><strong>التحذيرات والاحتياطات&nbsp;</strong><br />تحدث مع طبيبك أو الصيدلي قبل تناول عقار إزيورال:&nbsp;</p><ul><li>إذا كنت تعاني من مشاكل حادة في الكبد.&nbsp;</li><li>إذا كنت تعاني من مشاكل حادة في الكُلى.&nbsp;</li></ul><p>قد يتسبب إزيورال في إخفاء أعراض الأمراض الأخرى. لذلك، <strong>إذا حدث لك أي مما يلي قبل تناول عقار إزيورال أو أثناء فترة تناوله، يجب عليك التحدث إلى طبيبك في الحال:&nbsp;</strong></p><ul><li>فقدان الكثير من الوزن بدون سبب ووجود مشاكل في البلع.&nbsp;</li><li>الشعور بألم في المعدة أو عُسر هضم.&nbsp;</li><li>البدء في تقيؤ الطعام أو الدم.&nbsp;</li><li>إخراج براز أسود (براز ملطخ بالدماء).&nbsp;</li></ul><p>إذا كنت تتناول عقار إزيورال بدون وصفة طبية ينبغي عليك الاتصال بطبيبك في حال استمرار أعراضك أو حدوث تغير في طبيعتها.&nbsp;</p><p>إن تناول مثبطات ضخ البروتون مثل عقار إزيورال لفترة طويلة تتعدى السنة قد يتسبب في حدوث زيادة طفيفة لخطر الإصابة بكسر في منطقة الفخذ أو المعصم أو العمود الفقري. اخبر طبيبك إذا كنت تعاني من هشاشة العظام أو إذا كنت تتناول الكورتيكوستيرويدات (والتي يمكن أن تزيد من خطر الإصابة بهشاشة العظام).</p><p>&nbsp;</p><p><strong>الأطفال تحت سن 12 سنة&nbsp;</strong><br />ينبغي عدم إعطاء عقار إزيورال للأطفال تحت سن 12 سنة. تتاح أشكال دوائية أخرى من هذا الدواء قد تكون أكثر ملائمة لهذه الفئة العمرية.&nbsp;</p><p>&nbsp;</p><p><strong>الأدوية الأخرى وعقار إزيورال</strong><br />اخبر طبيبك أو الصيدلي ما إذا كنت تتناول، أو تناولت مؤخرًا أو قد تحتاج لتناول أي أدوية أخرى. ويشمل ذلك الأدوية التي تقوم بشرائها بدون وصفة طبية. ويرجع ذلك إلى أن عقار إزيورال قد يتداخل مع عمل بعض الأدوية الأخرى وقد يكون لبعض الأدوية تأثيرًا ما على عقار إزيورال.&nbsp;<br />لا تتناول عقار إزيورال إذا كنت تتناول دواء يحتوي على النلفينافير (يُستخدم في علاج مرض الإيدز).&nbsp;</p><p>&nbsp;</p><p>أخبر طبيبك أو الصيدلي إذا كنت تتناول أي من الأدوية التالية:&nbsp;</p><ul><li>اتازنفير (يُستخدم في علاج مرض الإيدز).&nbsp;</li><li>كلوبيدوجريل (يُستخدم لمنع تكون التجلطات الدموية).&nbsp;</li><li>كيتوكونازول أو إيتراكونازول أو فوريكونازول (يُستخدم في علاج العدوى التي تسببها الفطريات).&nbsp;</li><li>إرلوتينيب (يُستخدم في علاج السرطان).&nbsp;</li><li>سيتالوبرام أو إيميبرامين أو كلوميبرامين (يُستخدم في علاج الاكتئاب).&nbsp;</li><li>ديازيبام (يُستخدم في علاج القلق أو كباسط للعضلات أو لعلاج الصرع).&nbsp;</li><li>فينيتوين (يُستخدم لعلاج الصرع). إذا كنت تتناول الفينيتوين، فإن طبيبك سيحتاج لمتابعتك عند بدء تلقي عقار إزيورال أو إيقافه.&nbsp;</li><li>أدوية سيولة الدم، مثل وارفارين. يحتاج طبيبك لمتابعتك عند بدء تلقي عقار إزيورال أو إيقافه.&nbsp;</li><li>سيلوستازول (يُستخدم في علاج العرج المتقطع &ndash; وهو ألم في الساق عند المشي ناتج عن وصول الدم للساق بشكل كافي).&nbsp;</li><li>سيسابريد (يُستخدم في علاج عُسر الهضم وحرقة المعدة).&nbsp;</li><li>ديجوكسين (يُستخدم لعلاج مشاكل القلب).&nbsp;</li><li>ميثوتريكسات (علاج كيماوي يُستخدم بجرعات كبيرة لعلاج السرطان) &ndash; إذا كنت تتناول جرعة كبيرة من ميثوتريكسات، قد يقوم طبيبك بإيقافك عن تناول عقار إزيورال مؤقتًا.&nbsp;</li><li>تاكروليموس (يُستخدم مع حالات زراعة الأعضاء).&nbsp;</li><li>ريفامبيسين (يُستخدم في علاج مرض السل).&nbsp;</li><li>نبتة سانت جون (هيوفاريقفون مثقب) (تُستخدم في علاج الاكتئاب).&nbsp;</li></ul><p>إذا قام طبيبك بوصف المضادات الحيوية مثل الأموكسيسيلين و الكلاريثروميسين مع عقار إزيورال لعلاج القرحة الناتجة عن الإصابة بالبكتيريا الملوية البوابية، يجب عليك إخبار طبيبك بجميع الأدوية الأخرى التي تتناولها.&nbsp;</p><p>&nbsp;</p><p><strong>تناول إزيورال مع الطعام والشراب&nbsp;</strong><br />يمكنك تناول إزيورال مع الطعام أو على معدة فارغة.&nbsp;</p><p>&nbsp;</p><p><strong>الحمل والرضاعة والإخصاب&nbsp;</strong><br />إذا كنتِ حامل أو ترضعين رضاعة طبيعية أو إذا كنت تشكين في وجود حمل أو تخططين للإنجاب، استشيري طبيبك أو الصيدلي أولًا قبل تناول هذا الدواء.&nbsp;<br />يقرر طبيبك ما إذا كان بإمكانك تناول عقار إزيورال خلال تلك الفترة أم لا.&nbsp;<br />لا يوجد أي تأثيرات معروفة لدواء الإيزومبيرازول على الرضاعة الطبيعية. لذلك، ينبغي عليك عدم تناول عقار إزيورال أثناء الرضاعة.&nbsp;</p><p>&nbsp;</p><p><strong>قيادة المركبات واستخدام الآلات&nbsp;</strong><br />ليس من المحتمل أن يؤثر عقار إزيورال على قدرتك على القيادة أو استخدام أي أدوات أو آلات. إلا أن بعض الآثار الجانبية مثل الشعور بالدوار وعدم وضوح الرؤية تحدث نادرًا أو بشكل غير شائع (انظر القسم 4). إذا تأثرت بالدواء، ينبغي عليك تجنب القيادة أو استخدام الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول هذا الدواء دائمًا كما أشار طبيبك أو الصيدلي. راجع طبيبك أو الصيدلي إذا لم تكن متأكدًا من طريقة تناوله.&nbsp;</p><ul><li>إذا كنت تتناول هذا الدواء لفترة طويلة، سيحتاج طبيبك إلى متابعتك (خاصة إذا كنت تتناول هذا العقار لمدة تزيد عن السنة).&nbsp;</li><li>إذا أشار عليك طبيبك بتناول هذا الدواء عند الحاجة أو الضرورة، أخبر طبيبك إذا كان هناك أي تغير في الأعراض.&nbsp;</li></ul><p>&nbsp;</p><p><strong>الكمية التي يجب تناولها&nbsp;</strong></p><ul><li>يُخبرك طبيبك عن عدد الأقراص ومدة تناول الدواء. تتحدد الجرعة ومدة العلاج حسب حالتك، وعمرك وحالة أداء الكبد.&nbsp;</li><li>الجرعات الموصى بها مذكورة بالأسفل.&nbsp;</li></ul><p>&nbsp;</p><p><u>لعلاج حرقة المعدة الناتجة عن داء ارتجاع حمض المعدة (GERD):&nbsp;</u></p><p>البالغين واليافعين من عمر 12 عام أو أكثر:&nbsp;</p><ul><li>في حال وجد طبيبك أن المريء قد تضرر بشكل طفيف، تكون الجرعة الموصى بها قرصًا واحدًا من إزيورال 40 ملجم مرة واحدة يوميًا لمدة 4 أسابيع. قد يطلب منك طبيبك تناول نفس الجرعة لمدة 4 أسابيع أخرى إذا لم يكن المريء قد شُفي بالكامل بعد.&nbsp;</li><li>الجرعة الموصى بها بمجرد شفاء المريء هي قرص واحد من إزيورال 20 ملجم مرة واحدة يوميًا.&nbsp;</li><li>في حال عدم تعرض المريء للضرر، تكون الجرعة الموصى بها عبارة عن قرص واحد من إزيورال 20 ملجم يوميًا. بمجرد استقرار الحالة، قد يطلب منك طبيبك تناول الدواء حسب الحاجة أو الضرورة بحد أقصى قرص واحد يوميًا من إزيورال 20 ملجم.&nbsp;</li><li>إذا كنت تعاني من مشاكل حادة في الكبد، قد يحدد لك طبيبك جرعة أقل.&nbsp;</li></ul><p>&nbsp;</p><p><u>لعلاج قرحة المعدة الناتجة عن الإصابة بالبكتيريا الملوية البوابية ولمنع رجوعها مرة أخرى:</u></p><ul><li>البالغين واليافعين من عمر 12 عام أو أكثر: الجرعة الموصى بها هي قرص واحد من إزيورال 20 ملجم مرتين يوميًا لمدة أسبوع.&nbsp;</li><li>كما سينصحك طبيبك بتناول المضادات الحيوية، مثل الأموكسيسيلين والكلاريثروميسين.</li></ul><p>&nbsp;</p><p><u>لعلاج قرحة المعدة الناتجة عن تناول الأدوية غير الستيرويدية المضادة للالتهاب:</u> &nbsp;</p><ul><li>البالغين من عمر 18 عام أو أكثر: الجرعة الموصى بها هي قرص واحد من إزيورال 20 ملجم مرتين يوميًا لمدة 4 إلى 8 أسابيع.&nbsp;</li></ul><p>&nbsp;</p><p><u>لمنع حدوث قُرح المعدة في حال تناول الأدوية غير الستيرويدية المضادة للالتهاب:</u> &nbsp;</p><ul><li>البالغين من عمر 18 عام أو أكثر: الجرعة الموصى بها هي قرص واحد يوميًا من إزيورال 20 ملجم.&nbsp;</li></ul><p>&nbsp;</p><p><u>لعلاج زيادة الحمض في المعدة والتي يتسبب بها نمو في البنكرياس (متلازمة زولينجر-إليسون [فرط إفراز حمض المعدة بسبب ورم الغاسترين]):</u>&nbsp;</p><ul><li>البالغين من عمر 18 عام أو أكثر: الجرعة الموصى بها هي قرص واحد من إزيورال 40 ملجم مرتين يوميًا.&nbsp;</li><li>سيضبط لك طبيبك الجرعة حسب احتياجاتك كما سيحدد مدة تناولك لهذا الدواء. الحد الأقصى للجرعة هو 80 ملجم مرتين يوميًا.&nbsp;</li></ul><p>&nbsp;</p><p><u>الاستخدام في العلاج المطول بعد منع القرح من النزف مرة أخرى عن طريق الحقن الوريدي لدواء الإيزومبيرازول:</u>&nbsp;</p><ul><li>البالغين من عمر 18 عام أو أكثر: الجرعة الموصى بها هي قرص واحد من إزيورال 40 ملجم مرة يوميًا لمدة 4 أسابيع.</li></ul><p>&nbsp;</p><p><strong>تناول هذا العقار&nbsp;</strong></p><ul><li>يمكنك تناول جرعتك من الأقراص في أي وقت من اليوم.&nbsp;</li><li>يمكنك تناول إزيورال مع الطعام أو على معدة فارغة.&nbsp;</li><li>ابتلع جرعتك من الأقراص بالكامل بكوب من الماء. لا تمضغ الأقراص أو تطحنها. ويرجع ذلك إلى أن الأقراص تحتوي على حبيبات مغلفة تمنع حمض المعدة من تفتيتها. إن عدم إتلاف الحبيبات هام للغاية.</li></ul><p>&nbsp;</p><p><strong>ماذا تفعل إذا كنت تعاني من مشكلة في ابتلاع الأقراص</strong>&nbsp;</p><ul><li dir="rtl">إذا كنت تعاني من مشكلة في ابتلاع الأقراص:&nbsp;<ul><li>ضع الأقراص في نصف كوب من الماء المُقطر (غير الفوار). لا تستخدم أية سوائل أخرى.&nbsp;</li><li>حرك الأقراص في الماء حتى تنفصل (يتكون مزيج غير شفاف). ثم تناول المزيج مرة واحدة أو على مرات خلال 30 دقيقة. حرك المزيج في كل مرة قبل تناوله.&nbsp;</li><li>للتأكد من تناولك الدواء بأكمله، أملأ نصف الكوب بالمياه وحركه جيدًا ثم تناوله. لا تمضغ أو تطحن الأجزاء الصلبة التي تحتوي على الدواء.&nbsp;</li><li>إذا كنت لا تستطيع ابتلاع القرص بأي شكل من الأشكال، يمكنك خلطه بالقليل من الماء ووضعه في محقن. في هذه الحال يمكن إنزاله إلى معدتك مباشرة من خلال أنبوب (&laquo;أنبوب المعدة&raquo;).&nbsp;</li></ul></li></ul><p>&nbsp;</p><p><strong>الأطفال تحت سن 12 سنة&nbsp;</strong><br />ينبغي عدم إعطاء عقار إزيورال للأطفال تحت سن 12 سنة. تتاح أشكال دوائية أخرى من هذا الدواء قد تكون أكثر ملائمة لهذه الفئة العمرية.&nbsp;</p><p>&nbsp;</p><p><strong>كبار السن&nbsp;</strong><br />تعديل الجرعة غير لازم لكبار السن.&nbsp;</p><p>&nbsp;</p><p><strong>إذا كنت تتناول أكثر مما يجب من عقار إزيورال&nbsp;</strong><br />إذا تناولت من عقار إزيورال أكثر مما هو موصوفًا لك بواسطة طبيبك، تحدث مباشرة مع طبيبك أو مع الصيدلي.&nbsp;</p><p>&nbsp;</p><p><strong>إذا نسيت تناول عقار إزيورال</strong></p><ul><li>في حال نسيت تناول أحد الجرعات، تناولها بمجرد تذكرك. أما إذا كان موعد الجرعة التالية قد اقترب، في هذه الحالة يمكنك تخطي هذه الجرعة الفائتة.&nbsp;</li><li>لا تتناول جرعة مضاعفة (جرعتين في نفس الوقت) لتعويض الجرعة الفائتة.&nbsp;</li></ul><p>إذا كانت لديك أية استفسارات أخرى حول استخدام هذا العقار، فاسأل الطبيب أو الصيدلي.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل الأدوية الأخرى، قد يتسبب عقار إزيورال في بعض الآثار الجانبية لبعض الأشخاص. الآثار الجانبية التي تحدث عادةً ما تكون طفيفة. عادةً ما تذهب تلك الآثار بعد مدة قصيرة من بدء تناول عقار إزيورال. قد لا تحدث لك تلك الآثار الجانبية عند تناول عقار إزيورال، إلا أن طبيبك فقط هو من يمكنه تقييم ذلك. إذا أصبحت تلك الآثار الجانبية متعبة (أو تجاوزت فترة يوم إلى يومين)، ناقش طبيبك في الأمر.</p><p>&nbsp;</p><p><strong>إذا لاحظت أي من الآثار الجانبية الخطيرة التالية، توقف عن تناول عقار إزيورال واتصل بطبيبك على الفور:&nbsp;</strong></p><ul><li>صوت صفير مفاجئ عند التنفس، أو تورم في الشفتين أو اللسان والحلق أو الجسم، أو طفح جلدي، أو إغماء أو صعوبة في البلع (رد فعل تحسسي شديد).&nbsp;</li><li>إحمرار الجلد مع ظهور بثور أو وجود تقشير. قد يكون هناك أيضًا ظهور حاد للبثور ونزيف في الشفتين والعينين والفم والأنف والأعضاء التناسلية. قد تكون هذه الحالة هي &laquo;متلازمة ستيفنز-جونسون&raquo; أو &laquo;تقشر الانسجة المتموتة البشروية التسممي&raquo;.&nbsp;</li><li>وجود اصفرار بالجلد وتحول البول إلى اللون الداكن، والتي قد تكون أعراض لوجود مشاكل بالكبد.&nbsp;</li></ul><p>هذه الآثار الجانبية نادرة الحدوث (قد تحدث لشخص واحد من بين 1000 شخص).&nbsp;</p><p>&nbsp;</p><p>الآثار الجانبية الأخرى تشمل:&nbsp;</p><p><u>آثار جانبية شائعة (قد تحدث لشخص واحد من بين 10 أشخاص)</u></p><ul><li>الصداع.&nbsp;</li><li>التأثير على المعدة أو الأمعاء: إسهال، ألم بالمعدة، إمساك، الريح (غازات البطن).&nbsp;</li><li>الشعور بالإعياء (الغثيان) أو الإعياء (التقيؤ).&nbsp;</li></ul><p>&nbsp;</p><p><u>آثار جانبية غير شائعة (قد تحدث لشخص واحد من بين 100 شخص)</u></p><ul><li>تورم القدمين والكاحلين.&nbsp;</li><li>اضطرابات النوم (الأرق).&nbsp;</li><li>الدوار، الشعور بالوخز مثل &laquo;وخز الدبابيس والإبر&raquo;، الشعور بالنُعاس.&nbsp;</li><li>شعور بالدوخة (الدوار).&nbsp;</li><li>جفاف الفم.&nbsp;</li><li>تغير في نتائج اختبارات وظائف الكبد التي تُجرى عن طريق تحليل الدم.&nbsp;</li><li>طفح جلدي، طفح جلدي عقدي (الشرى) وحكة في الجلد.&nbsp;</li><li>كسر في الفخذ أو المعصم أو العمود الفقري (في حال استخدم عقار إزيورال بجرعات كبيرة ولمدة طويلة).&nbsp;</li></ul><p>&nbsp;</p><p><u>آثار جانبية نادرة (قد تحدث لشخص واحد من بين 1,000 شخص)</u></p><ul><li>مشاكل في الدم مثل انخفاض نسبة كريات الدم البيضاء أو الصفائح الدموية. قد يسبب ذلك الضُعف، أو التَكَدُّم أو يزيد من احتمال الإصابة بالعدوى.&nbsp;</li><li>انخفاض مستويات الصوديوم في الدم. قد يُسبب ذلك الضعف أو الإعياء (التقيؤ) والمغص.&nbsp;</li><li>الشعور بالهياج أو الارتباك أو الإحباط.&nbsp;</li><li>تغير المذاق.&nbsp;</li><li>مشاكل في الرؤية مثل تغيم الرؤية.&nbsp;</li><li>صوت صفير مفاجئ عند التنفس أو ضيق التنفس (تشنج قصبي).&nbsp;</li><li>التهاب في الفم من الداخل.</li><li>الإصابة بعدوى &laquo;مرض القلاع&raquo; التي يمكن أن تؤثر على الأمعاء والتي تسببها الفطريات.&nbsp;</li><li>مشاكل في الكبد، ومنها اليرقان (الصفراء) والذي يمكن أن يُسبب اصفرار الجلد وتحول البول إلى اللون الداكن والشعور بالإرهاق. &nbsp;</li><li>سقوط الشعر.&nbsp;</li><li>طفح جلدي عند التعرض للشمس.&nbsp;</li><li>ألم المفاصل أو ألم العضلات.&nbsp;</li><li>الشعور العام بعدم الارتياح وفقدان الطاقة.&nbsp;</li><li>زيادة التعرق.&nbsp;</li></ul><p>&nbsp;</p><p><u>آثار جانبية نادرة جدًا (قد تحدث لشخص واحد من بين 10,000 شخص)</u>&nbsp;</p><ul><li>تغيير في تعداد كريات الدم ويتضمن ندرة المحببات (قلة كريات الدم البيضاء).&nbsp;</li><li>العدوانية.&nbsp;</li><li>رؤية أشياء غير موجودة أو سماعها أو الشعور بها (هلوسات).&nbsp;</li><li>مشاكل حادة بالكبد تؤدي إلى فشل في الكبد والتهاب في المخ.&nbsp;</li><li>ظهور مفاجئ لطفح جلدي حاد أو بثور أو تقشير للجلد. قد يصاحب ذلك حُمى مفاجئة أو ألم في المفاصل (الحمامي عديدة الأشكال، متلازمة ستيفنز-جونسون، تقشر الانسجة المتموتة البشروية التسممي).&nbsp;</li><li>ضعف العضلات.&nbsp;</li><li>مشاكل حادة بالكُلى.&nbsp;</li><li>ظاهرة التثدي في الرجال.&nbsp;</li></ul><p>&nbsp;</p><p><u>آثار جانبية غير معروفة (لا يمكن تحديد تكرار هذه الآثار من البيانات المتوفرة)</u>&nbsp;</p><ul><li>إذا كنت تتناول عقار إزيورال لمدة تزيد عن الثلاثة أشهر فأنت مُعرض لانخفاض الماغنسيوم في دمك. يُمكن أن يظهر انخفاض الماغنسيوم في دمك في صورة الشعور بالتعب أو تقلص العضلات اللاإرادية أو التشوش الذهني أو التشنجات أو الدوخة أو زيادة معدل ضربات القلب. إذا شعرت بأي من هذه الأعراض، يُرجى إخبار طبيبك على الفور. قد يؤدي انخفاض مستويات الماغنسيوم إلى انخفاض مستويات البوتاسيوم أو الكالسيوم في الدم. قد يقرر طبيبك خضوعك الدوري لإجراء اختبار للدم لمراقبة مستويات الماغنسيوم في دمك.&nbsp;</li><li>التهاب في الأمعاء (يؤدي إلى إسهال).&nbsp;</li></ul><p>قد يؤثر عقار إزيورال في حالات نادرة جداً على خلايا الدم البيضاء الذي يؤدي بدوره إلى نقص المناعة. إذا كنت تعاني من الإصابة بأعراض مثل الحُمى مع تدهور حاد في حالتك العامة أو حُمى مع وجود أعراض حدوث عدوى موضعية مثل ألم الرقبة أو الحلق أو الفم أو صعوبة في التبول، يجب عليك استشارة طبيبك في أسرع وقت ممكن حتى يمكن استبعاد نقص كريات الدم البيضاء (ندرة المحببات) بإجراء اختبار للدم. من الأهمية بمكان إعطاء طبيبك معلومات حول الأدوية التي تتناولها في ذلك الوقت.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li>يٌحفظ في درجة حرارة أقل من 30 درجة مئوية. يٌحفظ بعيداً عن الرطوبة.</li><li>لا تترك عقار إزيورال في خزانة الأدوية بالحمام أو في أي أماكن رطبة ودافئة أخرى.</li><li>احتفظ بعقار إزيورال بعيدًا عن متناول أيدي ورؤية الأطفال الأطفال.</li><li>لا تستخدم عقار إزيورال بعد انتهاء تاريخ الصلاحية الموجود على العبوة.</li><li>لا تتخلص من أية أدوية في الصرف الصحي أو مع النفايات المنزلية. أسأل الصيدلي عن طريقة التخلص من الأدوية التي لم تعُد مُستخدمة. تساعد هذه التدابير في حماية البيئة.<br />&nbsp;</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li>المادة الفعالة هي إيزومبيرازول الماغنسيوم.&nbsp;</li><li>يحتوي كل قرص من إزيورال 20 ملجم على 20 ملجم من الإيزومبيرازول (في شكل إيزومبيرازول الماغنسيوم).&nbsp;</li><li>يحتوي كل قرص من إزيورال 40 ملجم على 40 ملجم من الإيزومبيرازول (في شكل إيزومبيرازول الماغنسيوم).&nbsp;</li></ul><p><strong>المكونات الأخرى&nbsp;</strong><br />يحتوي عقار إزيورال على المكونات التالية غير الدوائية (والمرتبة ترتيبًا أبجديًا): ثنائي أوكسيد السيليكون الغروي، كوبوفيدون، سترات الماغنسيوم، بوليمرات حمض الميثاكريليك المشتركة من النوع C، أكسيد الحديديك الأحمر، التلك، ثاني أكسيد التيتانيوم، ثلاثى السترات وأكسيد الحديديك الأصفر.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><u>الشكل الدوائي</u><br />أقراص-20 و 40 ملجم</p><p><u>الوصف المادي</u></p><ul><li>أقراص إزيورال 20 ملجم هي أقراص زهرية فاتحة اللون، بيضاوية، مغلفة. عبارة &laquo;ES20&raquo; محفورة على إحدى وجهي القرص.</li><li>أقراص إزيورال 40 ملجم هي أقراص وردية معتمة، بيضاوية، مغلفة. عبارة &laquo;ES40&raquo; محفورة على إحدى وجهي القرص.</li></ul><p><u>محتويات العبوة</u><br />الأقراص متوفرة في شرائط بكل شريط 20 قرص أو 30 قرص.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة أبوتكس&nbsp;<br />150 سيجنت درايف<br />تورنتو، أونتاريو<br />كندا، M9L 1T9<br />هاتف: 4623-268-800-1، فاكس: 9444-609-800-1<br />www.apotex.com<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             تمت آخر مراجعة لهذه النشرة بتاريخ 06/2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Trade Name in GCC: Esural Tablets
Trade Name in Country of Origin: Apo- Esomeprazole Tablets
Generic Name: Esomeprazole Magnesium Delayed Release Tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CORE

Esomeprazole  Magnesium (#):
Active ingredient
20mg tablet: 20.7 mg/tablet or 10.35% w/w
40mg tablet: 41.4 mg/tablet or 10.35% w/w

Copovidone (Kollidon VA64) EP (##):
Binder
20mg tablet: 175.6 mg/tablet or 87.8% w/w
40mg tablet: 351.2 mg/tablet or 87.8% w/w

Colloidal Silicon Dioxide NF:
Glidant/Anti-Adherent
20mg tablet: 0.5 mg/tablet or 0.25% w/w
40mg tablet: 1.0 mg/tablet or 0.25% w/w

Magnesium Stearate NF (Vegetable Source):
Lubricant
20mg tablet: 3.2 mg/tablet or 1.6% w/w
40mg tablet: 6.4 mg/tablet or 1.6% w/w

ENTERIC COATING

Triethyl Citrate NF (Citroflex 2)
Plasticizer
20mg tablet: 0.75 mg/tablet or 0.70% w/w
40mg tablet: 0.90 mg/tablet or 0.70% w/w

Talc USP 500 mesh
Glidant/Anti-caking Agent
20mg tablet: 1.75 mg/tablet or 1.64% w/w
40mg tablet: 2.1 mg/tablet or 1.64% w/w

Titanium Dioxide USP
Pigment/Opacifier
20mg tablet: 3.96 mg/tablet or 3.72% w/w
40mg tablet: 4.7 mg/tablet or 3.67% w/w

Red-Ferric Oxide NF (Orange Shade #34690)
Colouring Agent
20mg tablet: 0.03 mg/tablet or 0.03% w/w
40mg tablet: 0.25 mg/tablet or 0.20% w/w

Yellow Ferric Oxide NF
Colouring Agent
20mg tablet: 0.03 mg/tablet or 0.03% w/w
40mg tablet: 0.25 mg/tablet or 0.20% w/w

Methacrylic Acid	Copolymer Dispersion NF (30% Solids)
Polymer
20mg tablet: 25 (7.5**) mg/tablet or 23.47% w/w
40mg tablet: 30 (9.0**) mg/tablet or 23.44% w/w

Purified Water USP*
Solvent/Carrier
20mg tablet: 75 mg/tablet or 70.42% w/w
40mg tablet: 90 mg/tablet or 70.31% w/w

Total Coating Solution
20mg tablet: 106.5 mg/tablet or 100% w/w
40mg tablet: 128 mg/tablet or 100% w/w

Total Coating Solution (excluding water)
20mg tablet: 14 mg/tablet
40mg tablet: 17 mg/tablet

Total Tablet Weight
20mg tablet: 214 mg/tablet
40mg tablet: 417 mg/tablet

# 10.35% Esomeprazole  Magnesium is equivalent to 10.00% Esomeprazole.
## The amount of Copovidone added is adjusted based on the potency of Esomeprazole Magnesium.
* Purified water evaporates during the coating procedure.
** Methacrylic Acid Copolymer Dispersion NF contains 30% solids. The amounts in the brackets represent the solid content of Methacrylic Acid Copolymer Dispersion NF.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pharmaceutical form
Tablets for oral administration – 20 & 40 mg

ESURAL20 mg Tablets:  Light pink, oval, biconvex, enteric-coated tablet. Engraved "ES20" on one side, other side plain.

ESURAL40 mg Tablets: Dusty rose, oval, biconvex, enteric-coated tablet. Engraved "ES40" on one side, other side plain.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Esural is indicated for the short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>The recommended dose is 20 mg esomeprazole (one capsule) per day.</p><p>It might be necessary to take the capsules for 2-3 consecutive days to achieve improvement of symptoms. The duration of treatment is up to 2 weeks. Once complete relief of symptoms has occurred, treatment should be discontinued.</p><p>If no symptom relief is obtained within 2 weeks of continuous treatment, the patient should be instructed to consult a doctor.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><u>Patients with renal impairment</u></p><p>Dose adjustment is not required in patients with impaired renal function. Due to limited experience in patients with severe renal insufficiency, such patients should be treated with caution (see section 5.2).</p><p>&nbsp;</p><p><u>Patients with hepatic impairment</u></p><p>Dose adjustment is not required in patients with mild to moderate liver impairment. However, patients with severe liver impairment should be advised by a doctor before taking Esural (see sections 4.4 and 5.2).</p><p>Elderly patients (&ge;65 years old)</p><p>Dose adjustment is not required in elderly patients.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>There is no relevant use of Esural in the paediatric population below 18 years of age for the indication of &ldquo;short-term treatment of reflux symptoms (e.g., heartburn and acid regurgitation)&rdquo;.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>The capsules should be swallowed whole with half a glass of water. The capsules must not be chewed, crushed or opened.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, substituted benzimidazoles or to any of the excipients listed in section 6.1.

Esomeprazole must not be used concomitantly with nelfinavir (see section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General</u></p><p>Patients should be instructed to consult a doctor if:</p><ul><li>They have significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis or melaena and when gastric ulcer is suspected or present, malignancy should be excluded as treatment with esomeprazole may alleviate symptoms and delay diagnosis.</li><li>They have had previous gastric ulcer or gastrointestinal surgery.</li><li>They have been on continuous symptomatic treatment of indigestion or heartburn for 4 or more weeks.</li><li>They have jaundice or severe liver disease.</li><li>They are aged over 55 years with new or recently changed symptoms.</li></ul><p>Patients with long-term recurrent symptoms of indigestion or heartburn should see their doctor at regular intervals. Patients over 55 years taking any non-prescription indigestion or heartburn remedy on a daily basis should inform their pharmacist or doctor.</p><p>Patients should not take Esural as a long term preventive medicinal product.</p><p>Treatment with proton pump inhibitors (PPIs) may lead to a slightly increased risk of gastrointestinal infections such as Salmonella and Campylobacter and in hospitalised patients, also possibly Clostridium difficile (see section 5.1).</p><p>Patients should consult their doctor before taking this medicinal product if they are due to have an endoscopy or urea breath test.</p><p>&nbsp;</p><p><u>Combination with other medicinal products</u></p><p>Co-administration of esomeprazole with atazanavir is not recommended (see section 4.5). If the combination of atazanavir with a PPI is judged unavoidable, close clinical monitoring is recommended in combination with an increase in the dose of atazanavir to 400 mg with 100 mg of ritonavir. Esomeprazole 20 mg should not be exceeded.</p><p>&nbsp;</p><p>Esomeprazole is a CYP2C19 inhibitor. When starting or ending treatment with esomeprazole, the potential for interactions with medicinal products metabolised through CYP2C19 should be considered. An interaction is observed between clopidogrel and esomeprazole. The clinical relevance of this interaction is uncertain. The use of esomeprazole with clopidogrel should be discouraged (see section 4.5).</p><p>Patients should not take another PPI or H2 antagonist concomitantly.</p><p>&nbsp;</p><p><em>Interference</em><em> </em><em>with laboratory tests</em></p><p>Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. To avoid this interference, Esural treatment should be stopped for at least 5 days before CgA measurements (see section 5.1). If CgA and gastrin levels have not returned to reference range after initial measurement, measurements should be repeated 14 days after cessation of proton pump inhibitor treatment.</p><p>&nbsp;</p><p><em>Subacute cutaneous lupus erythematosus (SCLE)</em></p><p>Proton pump inhibitors are associated with very infrequent cases of SCLE. If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the health care professional should consider stopping Esural. SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with other proton pump inhibitors.</p><p>&nbsp;</p><p><em>Sucrose</em></p><p>This medicinal product contains sugar spheres (sucrose). Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies have only been performed in adults.</p><p>Effects of esomeprazole on the pharmacokinetics of other medicinal products</p><p>As esomeprazole is one enantiomer of omeprazole it is reasonable to advise about interactions reported with omeprazole.</p><p>&nbsp;</p><p><em>Protease</em><em> </em><em>inhibitors</em></p><p>Omeprazole has been reported to interact with some protease inhibitors. The clinical importance and the mechanisms behind these reported interactions are not always known. Increased gastric pH during omeprazole treatment may change the absorption of the protease inhibitors. Other possible interaction mechanisms are via inhibition of CYP2C19.</p><p>For atazanavir and nelfinavir, decreased serum levels have been reported when given together with omeprazole and concomitant administration is not recommended. Co-administration of omeprazole (40 mg once daily) with atazanavir 300 mg/ritonavir 100 mg to healthy volunteers resulted in a substantial reduction in atazanavir exposure (approximately 75% decrease in AUC, Cmax, and Cmin). Increasing the atazanavir dose to 400 mg did not compensate for the impact of omeprazole on atazanavir exposure. The co-administration of omeprazole (20 mg once a day) with atazanavir 400 mg/ritonavir 100 mg to healthy volunteers resulted in a decrease of approximately 30% in the atazanavir exposure as compared with the exposure observed with atazanavir 300 mg/ritonavir 100 mg once a day without omeprazole 20 mg once a day. Co-administration of omeprazole (40 mg once a day) reduced mean nelfinavir AUC, Cmax, and Cmin by 36 - 39 % and mean AUC, Cmax, and Cmin for the pharmacologically active metabolite M8 was reduced by 75 - 92%. Due to the similar pharmacodynamic effects and pharmacokinetic properties of omeprazole and esomeprazole, concomitant administration with esomeprazole and atazanavir is not recommended and concomitant administration with esomeprazole and nelfinavir is contraindicated (see section 4.3 and 4.4).</p><p>For saquinavir (with concomitant ritonavir), increased serum levels (80-100%) have been reported during concomitant omeprazole treatment (40 mg once a day). Treatment with omeprazole 20 mg once a day had no effect on the exposure of darunavir (with concomitant ritonavir) and amprenavir (with concomitant ritonavir).</p><p>Treatment with esomeprazole 20 mg once a day had no effect on the exposure of amprenavir (with and without concomitant ritonavir). Treatment with omeprazole 40 mg once a day had no effect on the exposure of lopinavir (with concomitant ritonavir).</p><p>&nbsp;</p><p><em><u>Methotrexate</u></em></p><p>When given together with PPIs, methotrexate levels have been reported to increase in some patients. In high-dose methotrexate administration a temporary withdrawal of esomeprazole may need to be considered.</p><p>&nbsp;</p><p><em><u>Tacrolimus</u></em></p><p>Concomitant administration of esomeprazole has been reported to increase the serum levels of tacrolimus. A reinforced monitoring of tacrolimus concentrations as well as renal function (creatinine clearance) should be performed, and the dose of tacrolimus adjusted if needed.</p><p>Medicinal products with pH dependent absorption</p><p>Gastric acid suppression during treatment with esomeprazole and other PPIs might decrease or increase the absorption of medicinal products with a gastric pH dependent absorption. The absorption of medicinal products taken orally such as ketoconazole, itraconazole and erlotinib can decrease during treatment with esomeprazole and the absorption of digoxin can increase during treatment with esomeprazole.</p><p>Concomitant treatment with omeprazole (20 mg daily) and digoxin in healthy subjects increased the bioavailability of digoxin by 10% (up to 30% in two out of ten subjects). Digoxin toxicity has been rarely reported. However, caution should be exercised when esomeprazole is given at high doses in elderly patients. Therapeutic monitoring of digoxin should then be reinforced.</p><p>&nbsp;</p><p><em><u>Medicinal</u></em><em><u> products metabolised by CYP2C19</u></em></p><p>Esomeprazole inhibits CYP2C19, the major esomeprazole metabolising enzyme. Thus, when esomeprazole is combined with medicinal products metabolised by CYP2C19, such as warfarin, phenytoin, citalopram, imipramine, clomipramine, diazepam, etc., the plasma concentrations of these medicinal products may be increased and a dose reduction could be needed. In case of clopidogrel, a prodrug which is transformed into its active metabolite via CYP2C19, the plasma concentrations of the active metabolite may be decreased.</p><p>&nbsp;</p><p><em><u>Warfarin</u></em></p><p>Concomitant administration of 40 mg esomeprazole to warfarin-treated patients in a clinical study showed that coagulation times were within the accepted range. However, post-marketing, a few isolated cases of elevated INR of clinical significance have been reported during concomitant treatment. Monitoring is recommended when initiating and ending concomitant esomeprazole treatment during treatment with warfarin or other coumarine derivatives.</p><p>&nbsp;</p><p><em><u>Clopidogrel</u></em></p><p>Results from studies in healthy subjects have shown a pharmacokinetic (PK)/pharmacodynamic (PD) interaction between clopidogrel (300 mg loading dose/75 mg daily maintenance dose) and esomeprazole (40 mg orally daily) resulting in decreased exposure to the active metabolite of clopidogrel by an average of 40%, and resulting in decreased maximum inhibition of (ADP induced) platelet aggregation by an average of 14%.</p><p>In a study in healthy subjects, there was a decreased exposure by almost 40% of the active metabolite of clopidogrel when a fixed dose combination of esomeprazole 20 mg + acetylsalicylic acid 81 mg was given with clopidogrel compared to clopidogrel alone. However, the maximum levels of inhibition of (ADP induced) platelet aggregation in these subjects were the same in both groups.</p><p>Inconsistent data on the clinical implications of this PK/PD interaction in terms of major cardiovascular events have been reported from both observational and clinical studies. As a precaution, concomitant use of esomeprazole and clopidogrel should be discouraged.</p><p>&nbsp;</p><p><em><u>Phenytoin</u></em></p><p>Concomitant administration of 40 mg esomeprazole resulted in a 13% increase in trough plasma levels of phenytoin in epileptic patients. It is recommended to monitor the plasma concentrations of phenytoin when treatment with esomeprazole is introduced or withdrawn.</p><p>&nbsp;</p><p><em><u>Voriconazole</u></em></p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t75" style='position:absolute;
 left:0;text-align:left;margin-left:532.55pt;margin-top:10.8pt;width:6pt;
 height:7.5pt;z-index:-34960;mso-position-horizontal-relative:page'>
 <v:imagedata src="file:///C:/Users/ahmed/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="8" height="10" src="file:///C:/Users/ahmed/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" />Omeprazole (40 mg once daily) increased voriconazole (a CYP2C19 substrate) Cmax and AUC&nbsp; &nbsp;by 15% and 41%, respectively.</p><p>&nbsp;</p><p><em><u>Cilostazol</u></em></p><p>Omeprazole as well as esomeprazole act as inhibitors of CYP2C19. Omeprazole, given in doses of 40 mg to healthy subjects in a cross-over study, increased Cmax and AUC for cilostazol by 18% and 26% respectively, and one of its active metabolites by 29% and 69% respectively.</p><p>&nbsp;</p><p><em><u>Cisapride</u></em></p><p>In healthy volunteers, concomitant administration of 40 mg esomeprazole resulted in a 32% increase in area under the plasma concentration-time curve (AUC) and a 31% prolongation of elimination half- life(t1/2) but no significant increase in peak plasma levels of cisapride. The slightly prolonged QTc interval observed after administration of cisapride alone, was not further prolonged when cisapride was given in combination with esomeprazole.</p><p>&nbsp;</p><p><em><u>Diazepam</u></em></p><p>&nbsp;</p><p>Concomitant administration of 30 mg esomeprazole resulted in a 45% decrease in clearance of the CYP2C19 substrate diazepam.</p><p>&nbsp;</p><p><em><u>Investigated</u></em><em><u> medicinal products with no clinically relevant interaction</u></em><em> </em><em>Amoxicillin</em><em> and quinidine</em></p><p>Esomeprazole has been shown to have no clinically relevant effects on the pharmacokinetics of amoxicillin and quinidine.</p><p>&nbsp;</p><p><em>Naproxen or rofecoxib</em></p><p>Studies evaluating concomitant administration of esomeprazole and either naproxen or rofecoxib did not identify any clinically relevant pharmacokinetic interactions during short-term studies.</p><p>&nbsp;</p><p><em><u>Effects</u></em><em><u> </u></em><em><u>of other medicinal products on the pharmacokinetics of esomeprazole</u></em><em> </em><em><u>Medicinal</u></em><em><u> products which inhibit CYP2C19 and/or CYP3A4</u></em></p><p>Esomeprazole is metabolised by CYP2C19 and CYP3A4. Concomitant administration of esomeprazole and a CYP3A4 inhibitor, clarithromycin (500 mg twice a day (b.i.d.)), resulted in a doubling of the exposure (AUC) to esomeprazole. Concomitant administration of esomeprazole and a combined inhibitor of CYP2C19 and CYP3A4 may result in more than doubling of the esomeprazole exposure. The CYP2C19 and CYP3A4 inhibitor voriconazole increased omeprazole AUCt by 280%. A dose adjustment of esomeprazole is not regularly required in either of these situations. However, dose adjustment should be considered in patients with severe hepatic impairment and if long-term treatment is indicated.</p><p>&nbsp;</p><p><em><u>Medicinal</u></em><em><u> products which induce CYP2C19 and/or CYP3A4</u></em></p><p>Medicinal products known to induce CYP2C19 or CYP3A4 or both (such as rifampicin and St. John&#39;s wort (Hypericum perforatum)) may lead to decreased esomeprazole serum levels by increasing the esomeprazole metabolism.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>A moderate amount of data on pregnant women (between 300-1,000 pregnancy outcomes) indicate no malformative or feto/ neonatal toxicity of esomeprazole.</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).</p><p>As a precautionary measure, it is preferable to avoid the use of Esural during pregnancy.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>It is unknown whether esomeprazole/metabolites are excreted in human milk. There is insufficient information on the effects of esomeprazole in newborns/infants. Esomeprazole should not be used during breast-feeding.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Animal studies with the racemic mixture omeprazole, given by oral administration do not indicate effects with respect to fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Esomeprazole has minor influence on the ability to drive or use machines. Adverse reactions such as dizziness and visual disturbances are uncommon (see section 4.8). If affected, patients should not drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>Headache, abdominal pain, diarrhoea and nausea are among those adverse reactions that have been most commonly reported in clinical studies (and also from post-marketing use). In addition, the safety profile is similar for different formulations, treatment indications, age groups and patient populations. No dose- related adverse reactions have been identified.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>The following adverse reactions have been identified or suspected in the clinical studies programme for esomeprazole and post-marketing. The reactions are classified according to MedDRA frequency convention: very common (&ge; 1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="text-align:center; vertical-align:top"><p><strong>Common</strong></p></td><td style="text-align:center; vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="text-align:center; vertical-align:top"><p><strong>Rare</strong></p></td><td style="text-align:center; vertical-align:top"><p><strong>Very</strong><strong> </strong><strong>rare</strong></p></td><td style="text-align:center; vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>leukopenia, thrombocytopenia</p></td><td style="vertical-align:top"><p>agranulocytosis, pancytopenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypersensitivity reactions e.g. fever, angioedema and anaphylactic reaction/shock</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>peripheral oedema</p></td><td style="vertical-align:top"><p>hyponatraemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypomagne- saemia; severe hypomagne- saemia can correlate with hypocalcaemia; hypomagne- saemia may also result in hypokalaemia</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>insomnia</p></td><td style="vertical-align:top"><p>agitation, confusion, depression</p></td><td style="vertical-align:top"><p>aggression, hallucinations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="text-align:center; vertical-align:top">&nbsp;</td><td style="text-align:center; vertical-align:top"><strong>Common</strong></td><td style="text-align:center; vertical-align:top"><strong>Uncommon</strong></td><td style="text-align:center; vertical-align:top"><strong>Rare</strong></td><td style="text-align:center; vertical-align:top"><strong>Very</strong><strong> </strong><strong>rare</strong></td><td style="text-align:center; vertical-align:top"><strong>Not known</strong></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>headache</p></td><td style="vertical-align:top"><p>dizziness, paraesthesia, somnolence</p></td><td style="vertical-align:top"><p>taste disturbance</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>blurred vision</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>vertigo</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>bronchospasm</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>abdominal pain, constipation, diarrhoea, flatulence, nausea/ vomiting, fundic gland polyps (benign)</p></td><td style="vertical-align:top"><p>dry mouth</p></td><td style="vertical-align:top"><p>stomatitis, gastrointestinal candidiasis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>microscopic colitis</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>increased liver enzymes</p></td><td style="vertical-align:top"><p>hepatitis with or without jaundice</p></td><td style="vertical-align:top"><p>hepatic failure, hepatic encephalopathy in patients with pre- existing liver disease</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>dermatitis, pruritus, rash urticaria</p></td><td style="vertical-align:top"><p>alopecia, photosensitivity</p></td><td style="vertical-align:top"><p>erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN)</p></td><td style="vertical-align:top"><p>Subacute cutaneous lupus erythematosus (see section 4.4).</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>arthralgia, myalgia</p></td><td style="vertical-align:top"><p>muscular weakness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Interstitial nephritis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>gynaecomastia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>malaise, increased sweating</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>To report any side effects:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>Saudi Arabia:</em></strong></p><p><strong>The</strong><strong> </strong><strong>National</strong><strong> </strong><strong>Pharmacovigilance</strong><strong> </strong><strong>and</strong><strong> </strong><strong>Drug Safety Centre (NPC)</strong></p><ul><li>Fax: +966‐11‐205‐7662</li><li>Call NPC at +966‐11‐2038222, Exts: 2317‐2356‐2353‐2354‐2334‐2340.</li><li>Toll free phone: 8002490000</li><li>E‐mail: npc.drug@sfda.gov.sa</li><li>Website: www.sfda.gov.sa/npc</li></ul><p>&nbsp;</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:454px"><tbody><tr><td style="vertical-align:top; width:451px"><p><strong><em>Other</em></strong><strong><em> </em></strong><strong><em>GCC States:</em></strong></p><p>Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is very limited experience to date with deliberate overdose. The symptoms described in connection with 280 mg esomeprazole were gastrointestinal symptoms and weakness. Single doses of 80 mg esomeprazole were uneventful. No specific antidote is known. Esomeprazole is extensively plasma protein bound and is therefore not readily dialysable. Treatment should be symptomatic and general supportive measures should be utilised.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs for acid related disorders, proton pump inhibitors, ATC code: A02BC05.</p><p>Esomeprazole is the S-isomer of omeprazole and reduces gastric acid secretion through a specific targeted mechanism of action. It is a specific inhibitor of the acid pump in the parietal cell. Both the R- and S- isomer of omeprazole have similar pharmacodynamic activity.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Esomeprazole is a weak base and is concentrated and converted to the active form in the highly acidic environment of the secretory canaliculi of the parietal cell, where it inhibits the enzyme H+K+-ATPase (the acid pump) and inhibits both basal and stimulated acid secretion.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>After oral dosing with esomeprazole 20 mg and 40 mg the onset of effect occurs within one hour. After repeated administration with 20 mg esomeprazole once daily for five days, mean peak acid output after pentagastrin stimulation is decreased 90% when measured 6-7 hours after dosing on day five.</p><p>After five days of oral dosing with 20 mg and 40 mg of esomeprazole, intragastric pH above 4 was maintained for a mean time of 13 hours and 17 hours, respectively over 24 hours in symptomatic gastroesophageal reflux disease (GERD) patients. The proportion of patients maintaining an intragastric pH above 4 for at least 8, 12 and 16 hours respectively were for esomeprazole 20 mg 76%, 54%, and 24%.</p><p>Corresponding proportions for esomeprazole 40 mg were 97%, 92%, and 56%.</p><p>Using AUC as a surrogate parameter for plasma concentration, a relationship between inhibition of acid secretion and exposure has been shown.</p><p>During treatment with antisecretory medicinal products, serum gastrin increases in response to the decreased acid secretion. Also CgA increases due to decreased gastric acidity. The increased CgA level may interfere with investigations for neuroendocrine tumours.</p><p>Available published evidence suggests that proton pump inhibitors should be discontinued between 5 days and 2 weeks prior to CgA measurements. This is to allow CgA levels that might be spuriously elevated following PPI treatment to return to reference range.</p><p>An increased number of ECL cells possibly related to the increased serum gastrin levels, have been observed in some patients during long-term treatment with esomeprazole.</p><p>Decreased gastric acidity due to any means including PPIs, increases gastric counts of bacteria normally present in the gastrointestinal tract. Treatment with PPIs may lead to slightly increased risk of gastrointestinal infections such as Salmonella and Campylobacter and in hospitalised patients, also possibly Clostridium difficile.</p><p>&nbsp;</p><p><u>Clinical efficacy</u></p><p>Esomeprazole 20 mg has been demonstrated to effectively treat frequent heartburn in subjects receiving one dose per 24 hours over 2 weeks. In two multicentre, randomised, double-blind, placebo-controlled pivotal studies 234 subjects with a recent history of frequent heartburn were treated with 20 mg esomeprazole for 4 weeks. Symptoms associated with acid reflux (such as heartburn and acid regurgitation) were evaluated retrospectively over a 24 hour period. In both studies esomeprazole 20 mg was significantly better compared to placebo for the primary endpoint, complete resolution of heartburn, defined as no heartburn episodes during the last 7 days prior to the final visit (33.9% - 41.6% vs. placebo 11.9 - 13.7%, (p&lt;0.001). The secondary endpoint of complete resolution of heartburn, defined as no heartburn on the patient&#39;s diary card for 7 consecutive days, was statistically significant at both week 1 (10.0% - 15.2% vs. placebo 0.9% - 2.4%, p = 0.014, p&lt;0.001) and week 2 (25.2% - 35.7% vs. placebo 3.4% - 9.0%, p&lt;0.001).</p><p>Other secondary endpoints were supportive of the primary endpoint, including relief of heartburn at week 1 and week 2, percentage of 24 hour days without heartburn at week 1 and week 2, mean heartburn severity at week 1 and week 2, and time to initial and sustained resolution of heartburn over a 24 hour period and during the night compared to placebo. Approximately 78% of the subjects on 20 mg esomeprazole reported first resolution of heartburn within the first week of treatment compared to 52 - 58% for placebo. Time to sustained resolution of heartburn, defined as when 7 consecutive days of no heartburn was first recorded, was significantly shorter in the esomeprazole 20 mg group (39.7% - 48.7% by day 14 vs. placebo 11.0% - 20.2%). The median time to first resolution of night-time heartburn was 1 day, statistically significant compared to placebo in one study (p=0.048) and approaching significance in the other (p=0.069). About 80% of nights were heartburn free during all time periods and 90% of nights were heartburn free by week 2 of each clinical study, compared to 72.4 - 78.3% for placebo. The investigators&#39; assessments of heartburn resolution were consistent with the subjects&#39; assessments, showing statistically significant differences between esomeprazole (34.7% - 41.8%) compared to placebo (8.0% - 11.4%). The investigators also found esomeprazole to be significantly more effective than placebo in resolving acid regurgitation (58.5% - 63.6% vs. placebo 28.3% - 37.4%) during the week 2 evaluation.</p><p>Following Overall Treatment Evaluation (OTE) of patients at week 2, 78.0 - 80.7% of patients on esomeprazole 20 mg, compared to 72.4 - 78.3% for placebo, reported their condition as improved. The majority of these rated the importance of this change to be Important to Extremely Important in performing their activities of daily living (79 - 86% at week 2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Esomeprazole is acid labile and is administered orally as enteric-coated granules. In vivo conversion to the R-isomer is negligible. Absorption of esomeprazole is rapid, with peak plasma levels occurring approximately 1-2 hours after dose. The absolute bioavailability is 64% after a single dose of 40 mg and increases to 89% after repeated once-daily administration. For 20 mg esomeprazole the corresponding values are 50% and 68% respectively. Food intake both delays and decreases the absorption of esomeprazole although this has no significant influence on the effect of esomeprazole on intragastric acidity.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>The apparent volume of distribution at steady state in healthy subjects is approximately 0.22 l/kg body weight. Esomeprazole is 97% plasma protein bound.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Esomeprazole is completely metabolised by the cytochrome P450 system (CYP). The major part of the metabolism of esomeprazole is dependent on the polymorphic CYP2C19, responsible for the formation of the hydroxy- and desmethyl metabolites of esomeprazole. The remaining part is dependent on another specific isoform, CYP3A4, responsible for the formation of esomeprazole sulphone, the main metabolite in plasma.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>The parameters below reflect mainly the pharmacokinetics in individuals with a functional CYP2C19 enzyme, extensive metabolisers.</p><p>Total plasma clearance is about 17 l/h after a single dose and about 9 l/h after repeated administration. The plasma elimination half-life is about 1.3 hours after repeated once-daily dosing. Esomeprazole is completely eliminated from plasma between doses with no tendency for accumulation during once-daily administration. The major metabolites of esomeprazole have no effect on gastric acid secretion. Almost 80% of an oral dose of esomeprazole is excreted as metabolites in the urine, the remainder in the faeces.</p><p>Less than 1% of the parent compound is found in urine.</p><p>&nbsp;</p><p><u>Linearity/non-linearity</u></p><p>The pharmacokinetics of esomeprazole has been studied in doses up to 40 mg b.i.d. The area under the plasma concentration-time curve increases with repeated administration of esomeprazole. This increase is dose-dependent and results in a more than dose proportional increase in AUC after repeated administration. This time and dose-dependency is due to a decrease of first pass metabolism and systemic clearance probably caused by an inhibition of the CYP2C19 enzyme by esomeprazole and/or its sulphone metabolite.</p><p>&nbsp;</p><p><u>Special patient populations</u> <u>Poor metabolisers</u></p><p>Approximately 2.9&plusmn;1.5% of the population lack a functional CYP2C19 enzyme and are called poor metabolisers. In these individuals the metabolism of esomeprazole is probably mainly catalysed by CYP3A4. After repeated once-daily administration of 40 mg esomeprazole, the mean area under the plasma concentration-time curve was approximately 100% higher in poor metabolisers than in subjects having a functional CYP2C19 enzyme (extensive metabolisers). Mean peak plasma concentrations were 60% higher.</p><p>These findings have no implications for the posology of esomeprazole.</p><p>&nbsp;</p><p><em><u>Gender</u></em></p><p>Following a single dose of 40 mg esomeprazole the mean are under the plasma concentration-time curve is approximately 30% higher in females than in males. No gender difference is seen after repeated once-daily administration. These findings have no implications for the posology of esomeprazole.</p><p>&nbsp;</p><p><em><u>Hepatic</u></em><em><u> </u></em><em><u>impairment</u></em></p><p>The metabolism of esomeprazole in patients with mild to moderate liver dysfunction may be impaired. The metabolic rate is decreased in patients with severe liver dysfunction resulting in a doubling of the area under the plasma concentration-time curve of esomeprazole. Therefore, a maximum of 20 mg should not be exceeded in patients with severe dysfunction. Esomeprazole or its major metabolites do not show any tendency to accumulate with once-daily dosing.</p><p>&nbsp;</p><p><em><u>Renal impairment</u></em></p><p>No studies have been performed in patients with decreased renal function. Since the kidney is responsible for the excretion of the metabolites of esomeprazole but not for the elimination of the parent compound, the metabolism of esomeprazole is not expected to be changed in patients with impaired renal function.</p><p>&nbsp;</p><p><em><u>Elderly patie nts (&ge;65 y e ars old) </u></em></p><p>The metabolism of esomeprazole is not significantly changed in elderly patients (71-80 years of age).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no particular hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and toxicity to reproduction and development.</p><p>Adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels and with possible relevance to clinical use were as follows:</p><p>Carcinogenicity studies in the rat with the racemic mixture have shown gastric ECL-cell hyperplasia and carcinoids. These gastric effects in the rat are the result of sustained, pronounced hypergastrinaemia secondary to reduced production of gastric acid and are observed after long-term treatment in the rat with inhibitors of gastric acid secretion.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ESURAL contains the following non-medicinal ingredients (listed in alphabetical order): Colloidal silicon dioxide, Copovidone</p><p>Magnesium stearate</p><p>Methacrylic acid copolymer type c Red-ferric oxide</p><p>Talc</p><p>Titanium dioxide Triethyl citrate Yellow ferric oxide.</p><p>For the full quantitative composition, check Section 2.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C. Protect from moisture. No special precautions necessary.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Primary packaging:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Strength</p></td><td style="vertical-align:top"><p>Unit Count or Fill Size</p></td><td style="vertical-align:top"><p>Container Size(s)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Description</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>20 mg and</p><p>40 mg</p></td><td rowspan="2" style="vertical-align:top"><p>20s (10X2)</p></td><td rowspan="2" style="vertical-align:top"><p>Blisters</p></td><td style="vertical-align:top"><p>Cold &nbsp;Formable&nbsp;&nbsp; Foil &nbsp;205 &nbsp;MM: &nbsp;Dull &nbsp;silver &nbsp;on &nbsp;one side,&nbsp;&nbsp;&nbsp; shiny</p></td></tr><tr><td style="vertical-align:top"><p>silver&nbsp;&nbsp; on&nbsp; &nbsp;other.&nbsp;&nbsp; Rolled&nbsp;&nbsp; material approximately 205 mm wide.</p><p><u>White</u><u> Coated Foil 205MM </u>25UM: Light grey on one side, dull silver on other. Rolled material approximately 205 mm wide</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>20 mg and</p><p>40 mg</p></td><td rowspan="2" style="vertical-align:top"><p>30s (10X3)</p></td><td rowspan="2" style="vertical-align:top"><p>Blisters</p></td><td style="vertical-align:top"><p>Cold &nbsp;Formable&nbsp;&nbsp; Foil &nbsp;205 &nbsp;MM: &nbsp;Dull &nbsp;silver &nbsp;on &nbsp;one side,&nbsp;&nbsp;&nbsp; shiny</p></td></tr><tr><td style="vertical-align:top"><p>silver&nbsp;&nbsp; on&nbsp; &nbsp;other.&nbsp;&nbsp; Rolled&nbsp;&nbsp; material approximately 205 mm wide.</p><p><u>White</u><u> Coated Foil 205MM </u>25UM: Light grey on one side, dull silver on other. Rolled material approximately 205 mm wide .</p></td></tr></tbody></table><p>Secondary packaging: Outer carton</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Administration through gastric tube</u></p><ol><li>Put the tablet into an appropriate syringe and fill the syringe with approximately 25 ml water and approximately 5 ml air. For some tubes, dispersion in 50 ml water is needed to prevent the pellets from clogging the tube.</li><li>Immediately shake the syringe until tablet has disintegrated.</li><li>Hold the syringe with the tip up and check that the tip has not clogged.</li><li>Attach the syringe to the tube whilst maintaining the above position.</li><li>Shake the syringe and position it with the tip pointing down. Immediately inject 5-10 ml into the tube. Invert the syringe after injection and shake (the syringe must be held with the tip pointing up to avoid clogging of the tip).</li><li>Turn the syringe with the tip down and immediately inject another 5-10 ml into the tube. Repeat this procedure until the syringe is empty.</li><li>Fill the syringe with 25 ml of water and 5 ml of air and repeat step 5 if necessary to washdown any sediment left in the syringe. For some tubes, 50 ml water is needed.</li></ol><p>&nbsp;</p><p><u>Special precautions for disposal</u> None required</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Apotex Incorporated 
150 Signet Drive 
Toronto, Ontario Canada, M9L 1T9
Tel: 1-800-268-4623, 
Fax: 1-800-609-9444 
www.apotex.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                02/2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>